Table 4 Apolipoprotein E-adjusted estimates of the association of 5-hydroxytriptamine transporter gene-linked polymorphic region (5-HTTLPR) S-plus carriers with clinical characteristics in patients with Alzheimer’s disease (AD) according to to the presence of delusion symptom
All | AD-D | AD-noD | |||||||
|---|---|---|---|---|---|---|---|---|---|
p | OR | (95%CI) | p | OR | (95%CI) | p | OR | (95%CI) | |
MNA | 0.464 | 1.892 | (3.449 × 10−1 - 1.038 × 101) | 0.884 | 1.157 | (0.163–8.205) | 0.830 | 0.607 | (5.772 × 10−3 - 6.375 × 101) |
ADL | 0.930 | 0.978 | (0.582–1.640) | 0.702 | 0.886 | (0.478–1.644) | 0.200 | 0.449 | (0.132–1.528) |
IADL | 0.349 | 1.383 | (0.703–2.720) | 0.420 | 1.356 | (0.644–2.855) | 0.367 | 0.418 | (0.064–2.745) |
CIRS-CI | 0.979 | 1.007 | (0.582–1.750) | 0.605 | 0.848 | (0.454–1.583) | 0.154 | 3.162 | (0.667–15.002) |
ESS | 0.220 | 1.810 | (0.709–4.600) | 0.400 | 1.600 | (0.543–4.715) | 0.310 | 0.265 | (0.021–3.414) |
SPMSQ | 0.993 | 1.000 | (0.611–1.650) | 0.943 | 1.022 | (0.570–1.830) | 0.140 | 2.310 | (0.770–6.931) |
Age at onset | 0.706 | 1.380 | (0.259–7.350) | 0.539 | 0.528 | (0.069–4.031) | 0.320 | 6.104 | (1.748 × 10−1 - 2.132 × 102) |
Disease duration | 0.011 | 0.740 | (0.587–0.933) | 0.005 | 0.680 | (0.522–0.886) | 0.700 | 1.116 | (0.640–1.947) |
MMSE | 0.996 | 1.000 | (0.223–4.510) | 0.888 | 0.880 | (0.148–5.215) | 0.210 | 0.121 | (4.464 × 10−3 - 3.290) |
NPI | 0.950 | 0.854 | (4.530 × 10−3 - 1.610 × 102) | 0.235 | 4.796 × 101 | (8.237 × 10−2 - 2.792 × 104) | 0.420 | 5.490 × 101 | (3.419 × 10− 3 - 8.817 × 105) |
NPI-Distress | 0.870 | 1.180 | (0.153–9.150) | 0.074 | 9.564 | (8.161 × 10 −1 - 1.121 × 10 2 ) | 0.234 | 7.960 | (2.282 × 10−1 - 2.362 × 102) |